title: The effect of mitomycin C on corneal endothelium in pterygium surgery.
abstract: OBJECTIVE
  To evaluate the changes in endothelial cell counts in patients after pterygium surgery with mitomycin C (MMC) 0.02% and to compare them with patients undergoing pterygium excision without MMC.
  
  
  METHODS
  Prospective nonrandomized study.
  
  
  METHODS
  Forty-three consecutive patients were included in this study. Sixteen patients underwent pterygium surgery with conjunctival autograft and MMC for recurrent pterygium and 27 patients underwent pterygium excision without MMC for primary pterygium removal (control group) at the Toronto Western Hospital. Endothelial images were acquired at the center of the cornea with a specular microscope before surgery and at one week, one month, and three months following surgery.
  
  
  RESULTS
  Mean preoperative endothelial cell counts were 2330 +/- 318 cells/mm(2) in the pterygium excision without MMC group and 2486 +/- 327 cells/mm(2) in the pterygium excision with MMC group (P = .13). One month after surgery, the pterygium with MMC group showed a significant endothelial cell loss of 6% which was not present in the control group (P = .03). Three months after surgery, endothelial cell loss was reduced to 4%. (P = .08 compared with the control). In the pterygium excision with MMC group, endothelial polymeghatism was increased (at one and three months) and the percentage of hexagomal cells was reduced (at one month).
  
  
  CONCLUSIONS
  The use of topical MMC during recurrent pterygium surgery was found to have a deleterious effect on corneal endothelium one month following surgery. Judicious use of this drug is therefore recommended.
authors.affiliation: Ophthalmology Department, Toronto Western Hospital, University of Toronto, Ontario, Canada. iritbahar@yahoo.com
authors.forename: Irit
authors.initials: I
authors.lastname: Bahar
authors.forename: Igor
authors.initials: I
authors.lastname: Kaiserman
authors.forename: Alex P
authors.initials: AP
authors.lastname: Lange
authors.forename: Alana
authors.initials: A
authors.lastname: Slomovic
authors.forename: Eliya
authors.initials: E
authors.lastname: Levinger
authors.forename: Wiwan
authors.initials: W
authors.lastname: Sansanayudh
authors.forename: Allan R
authors.initials: AR
authors.lastname: Slomovic
mesh_terms: D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects*; D002452:Cell Count; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000637:transplantation*; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects*; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy / Q000601:surgery*; D014014:Tissue Adhesives / Q000627:therapeutic use; D014182:Transplantation, Autologous
chemical_list: D000477:Alkylating Agents; D015718:Fibrin Tissue Adhesive; D014014:Tissue Adhesives; D016685:Mitomycin